New Insights into Biology, Prognostic Factors, and Current Therapeutic Strategies in Chronic Lymphocytic Leukemia

Table 1

Larger studies in first-line treatment of CLL patients.

Trial	Regiments	𝑁	CR	OR	OS (months/% survivor at time)	Median PFS (months)
Dighiero et al. [14]	Chlorambucil	293	45%	49%	ND	ND
Eichhorst et al. [15]	Chlorambucil	100	0	51%	64	18
	versus fludarabine	93	7%	72%	46	19
Rai et al. [16]	Chlorambucil	181	4%	37%	56	14
	versus fludarabine	170	20%	63%	66	20
Eichhorst et al. [17]	Fludarabine	164	7%	83%	81% at 3 y	20
	versus FC	164	24%	94%	80% at 3 y	48
Robak et al. [18]	CC	192	47%	88%	62.4% at 4 y	28
	versus FC	203	46%	82%	60.6% at 4 y	27
Robak et al. [19]	Cladribine	174	21%	78%	45	27.2
	versus CC	171	29%	83%	48	22.4
	versus CMC	163	36%	80%	46	25.6
Hallek et al. [20]	FC	409	22%	88%	ND	52
	versus rituximab-FC	408	44%	95%	ND	53
Kay et al. [21]	PCR	64	41%	91%	ND	33
Knauf et al. [22]	Chlorambucil	157	2%	31%	ND	8.3
	versus bendamustine	162	31%	63%	ND	21.6
Thornton et al. [23]	HDMP	25	0%	77%	ND	12
Hillmen et al. [24]	Alemtuzumab	149	24%	83%	ND	14.6
	versus chlorambucil	148	2%	55%	ND	11.7

𝑁: number of patients in the trial, CR: complete response, PR: partial response, OR: overall response, OS: overall survival, PFS: progression-free survival, ND: no data, FC: fludarabine and cyclophosphamide CC: cladribine and cyclophosphamide, CMC: cladribine, cyclophosphamide, and mitoxantrone, PCR: pentostatin, cyclophosphamide, and rituximab, HDMP: high-dose methylprednisolone.